Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART B, 2013, Pages 1274-1284

  Fei, Yang ^a   Kostewicz, Edmund S ^a   Sheu, Ming Thau ^b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Biorelevant dissolution tests; Fenofibrate; Lipid based formulation; Oral absorption; Permeability; Physiologically based pharmacokinetic model

Indexed keywords

EXCIPIENT; FENOFIBRATE; MYRITOL 318; POLYSORBATE 20; POLYSORBATE 80; TOCOFERSOLAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; PRECIPITATION; PREDICTION; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIORELEVANT DISSOLUTION TESTS; FENOFIBRATE; LIPID-BASED FORMULATION; ORAL ABSORPTION; PERMEABILITY; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL;

ABSORPTION; ADMINISTRATION, ORAL; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DIFFUSION; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FASTING; FENOFIBRATE; GASTRIC JUICE; HUMANS; INTESTINAL ABSORPTION; LIPIDS; PARTICLE SIZE; PERMEABILITY; SENSITIVITY AND SPECIFICITY; SOFTWARE; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 84889101528     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.03.001     Document Type: Article

References (39)

1. C. Leuner, and J.B. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
2. S.F. Han, T.T. Yao, X.X. Zhang, L. Gan, C. Zhu, H.Z. Yu, and Y. Gan Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation Int. J. Pharm. 379 2009 18 24
3. A.J. Humberstone, and W.N. Charman Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug Deliv. Rev. 25 1997 103 128
4. C.W. Pouton Lipid formulation for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems Eur. J. Pharm. Sci. 11 2000 93 98
5. L. Hu, H. Wu, F. Niu, C. Yan, X. Yang, and Y. Jia Design of fenofibrate microemulsion for improved bioavailability Int. J. Pharm. 420 2011 251 255
6. P. Ratanabanangkoon, H. Guzman, O. Almarsson, D. Berkovitz, S. Tokarcyzk, A.B. Straughn, and H. Chen A high-throughput approach towards a novel formulation of fenofibrate in omega-3 oil Eur. J. Pharm. Sci. 33 2008 351 360
7. K. Mohsin, M.A. Long, and C.W. Pouton Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution J. Pharm. Sci. 98 2009 3582 3595
8. H.D. Williams, P. Sassene, K. Kleberg, J.C. Bakala-N'Goma, M. Calderone, V. Jannin, A. Igonin, A. Partheil, D. Marchaud, E. Jule, J. Vertommen, M. Maio, R. Blundell, H. Benameur, F. Carriere, A. Mullertz, C.J.H. Porter, and C.W. Pouton Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations J. Pharm. Sci. 101 2012 3360 3380
9. M.U. Anby, H.D. Williams, M. McIntosh, H. Benameur, G.A. Edwards, C.W. Pouton, and C.J.H. Porter Lipid digestion as a trigger for supersaturation evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems Mol. Pharm. 9 2012 2063 2079
10. J.B. Dressman, K. Thelen, and E. Jantratid Towards quantitative prediction of oral drug absorption Clin. Pharmacokinet. 47 2008 655 667
11. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2011 257 264
12. D. Juenemann, and J. Dressman Analytical methods for dissolution testing of nanosized drugs J. Pharm. Pharmacol. 64 2012 931 943
13. C. Wagner, E. Jantratid, F. Kesisoglou, M. Vertzoni, C. Reppas, and J.B. Dressman Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model Eur. J. Pharm. Biopharm. 82 2012 127 138
14. Y. Shono, E. Jantratid, and J.B. Dressman Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir Eur. J. Pharm. Biopharm. 79 2011 349 356
15. M.D. Muria, G. Lamberti, and G. Titomanlio Physiologically based pharmacokinetics: a simple, all purpose model Ind. Eng. Chem. Res. 49 2010 2969 2978
16. J.D. Wei, H.O. Ho, C.H. Chen, W.T. Ke, E.T.H. Chen, and M.T. Sheu Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system J. Pharm. Pharmacol. 62 2010 1685 1696
17. Y.M. Lin, J.Y. Wu, Y.C. Chen, Y.D. Su, W.T. Ke, H.O. Ho, and M.T. Sheu In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate Int. J. Nanomed. 6 2011 2445 2457
18. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
19. L.X. Yu An integrated model for determining causes of poor oral drug absorption Pharm. Res. 16 1999 1883 1887
20. C. Schiller, C.P. Frohlich, T. Giessmann, W. Siegmund, H. Monnikes, N. Hosten, and W. Weitschies Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 22 2005 971 979
21. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
22. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 1998 698 705
23. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm. 60 2005 413 417
24. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51
25. S. Klein The mini paddle apparatus-a useful tool in the early developmental stage? Experiences with immediate-release dosage forms Dissol. Technol. 13 4 2006 6 11
26. J. Najib Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation Clin. Ther. 24 2002 2022 2050
27. A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M. Tubic Grozdanis, T. Lenhardt, and P. Langguth Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Adv. Drug Deliv. Rev. 59 2007 419 426
28. M. Kataoka, Y. Masaoka, Y. Yamazaki, T. Sakane, H. Sezaki, and S. Yamashita In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs Pharm. Res. 20 2003 1674 1680
29. P. Buch, P. Languth, M. Kataoka, and S. Yamashita IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system J. Pharm. Sci. 98 2009 2001 2009
30. P. Buch, P. Holm, J.Q. Thomassen, D. Scherer, R. Branscheid, U. Kolb, and P. Langguth IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics J. Pharm. Sci. 99 2009 4427 4436
31. P. Artursson, and J. Karlsson Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 175 1991 880 885
32. R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test Pharm. Res. 23 2006 1144 1156
33. G.M. Grass Simulation models to predict oral drug absorption from in vitro data Adv. Drug Deliv. Rev. 23 1997 199 219
34. J. Dressman, and J. Kraemer Pharmaceutical Dissolution Testing 2005 Taylor & Francis Group Boca Raton, USA
35. T. O'Hara, A. Dunne, J. Butler, and J. Devane A review of methods used to compare dissolution profile data Pharm. Sci. Technol. Today 1 1998 214 223
36. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
37. V.H. Sunesen, R. Vedelsdal, H.G. Kristensen, L. Christrup, and A. Mullertz Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug Eur. J. Pharm. Sci. 24 2005 297 303
38. J.M. Cardot, and B.M. Davit In vitro-in vivo correlations: tricks and traps AAPS J. 14 2012 491 499
39. EMEA, Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98, 2010. < http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/01/WC500070039.pdf >.